Bicara Therapeutics initiates FORTIFI-HN01, a global Phase 2/3 trial evaluating ficerafusp alfa combined with pembrolizumab in first-line recurrent/metastatic head and neck squamous cell carcinoma.
Clinical trial results presented at ASCO GI demonstrate improved objective response rate and progression-free survival when combining ficerafusp alfa with Keytruda in EGFR+ anal cancer patients.
Bicara Therapeutics has presented new Phase 1/1b data for ficerafusp alfa, a novel bifunctional antibody targeting both EGFR and TGF-beta, in combination with pembrolizumab for advanced anal cancer treatment.